Brevicidine TFA
Based on 1 Customer Validation
Brevicidine TFA is an antimicrobial peptide with selective bactericidal activity against Gram-negative pathogens. Brevicidine TFA disrupts bacterial morphology by binding to lipopolysaccharide (LPS) on the bacterial cell membrane to form pores. Brevicidine TFA causes dissipation of intracellular proton motive force, outer membrane damage, inhibition of ATP biosynthesis and reactive oxygen species accumulation in bacterial cells. As a sensitizer, Brevicidine TFA exerts synergistic activity when combined with a variety of conventional antibiotics.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 97.81%
- Formule: C74H106N18O17·xC2HF3O2
- Masse moléculaire:1519.74 (free base)
-
Stockage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Activité biologique
Description
In Vitro
Brevicidine (0-2 μM; 20 h) TFA acts as a synergistic sensitizer. When combined with outer membrane-impermeable antibiotics (Erythromycin (HY-B0220), Azithromycin (HY-17506), Vancomycin (HY-B0671)) against Acinetobacter baumannii strains, it reduces the MIC by up to 128-fold at concentrations as low as 1 μM[1].
Brevicidine (0.125-4 μM; 25 min) TFA disrupts the outer membrane of Acinetobacter baumannii ATCC 17978 in a dose-dependent manner[1].
Brevicidine (1-4 μM; 1 h) TFA inhibits ATP synthesis and induces ROS production in Acinetobacter baumannii, and this effect is enhanced when used in combination with Erythromycin[1].
Brevicidine (1-16 mg/L; 20 h) TFA selectively inhibits Gram-negative pathogenic bacteria with an MIC range of 1-16 mg/L, and shows no activity against Gram-positive pathogenic bacteria[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (male)[1]
-
Dosage:5 mg/kg (monotherapy); 5 mg/kg (combined with 5 mg/kg Erythromycin)
-
Administration:i.v.; single dose
-
Result:Reduced the death rate of A. baumannii-infected mice from 80% to 60%; significantly reduced bacterial load in the liver and spleen.
Achieved 100% survival when combined with 5 mg/kg Erythromycin; showed greater reduction in bacterial loads across organs when combined with Erythromycin compared to monotherapy.
Chemical Information
-
Appearance Solid
-
Masse moléculaire 1519.74 (free base)
-
Formule C74H106N18O17·xC2HF3O2
-
Color White to off-white
-
Sequence
4-Methylhexanoyl-{d-Asn}-{d-Tyr}-{d-Trp}-{d-Orn}-{Orn}-Gly-{d-Orn}-Trp-Thr-Ile-Gly-Ser (Lactone: Thr9-Ser12)
-
Sequence Shortening
4-Methylhexanoyl-{d-Asn}-{d-Tyr}-{d-Trp}-{d-Orn}-{Orn}-G-{d-Orn}-WTIGS (Lactone: Thr9-Ser12)
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvant et solubilité
In Vitro:
H2O : ≥ 50 mg/mL
* "≥" means soluble, but saturation unknown.
Protocole
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Gram Staining of Tissue Sections
Gram staining of tissue sections is a histochemical technique used to differentiate Gram-positive and Gram-negative bacteria within histological specimens based on differences in bacterial cell wall structure and dye retention, adapted from classical bacteriological Gram staining into tissue-compatible “histological Gram stain” variants. In tissue applications, modifications of the Brown-Hopps and Brown-Brenn methods are commonly used to improve differentiation of microorganisms embedded within host connective tissue and to reduce overstaining or loss of Gram-negative signal, which are known limitations of earlier approaches. The principle relies on crystal violet-iodine complex retention in Gram-positive organisms and subsequent decolorization and counterstaining steps that allow contrast visualization of Gram-negative organisms against tissue background.
-
Bacterial live/dead nucleic-acid viability staining
The LIVE/DEAD bacterial viability staining method is based on differential permeability of nucleic-acid-binding fluorescent dyes, most commonly SYTO 9 and propidium iodide (PI), which enables discrimination of bacterial populations with intact versus compromised cytoplasmic membranes. SYTO 9 penetrates both intact and damaged bacterial membranes and binds nucleic acids to produce green fluorescence, whereas propidium iodide penetrates only cells with compromised membranes and fluoresces red while also reducing SYTO 9 signal through competitive binding and fluorescence interactions. The resulting fluorescence pattern is interpreted as a proxy for membrane integrity, which is widely used as an indicator of bacterial viability in microscopy, flow cytometry, and spectroscopic platforms. However, mechanistic studies show that SYTO 9 and PI interactions involve displacement and fluorescence resonance energy transfer effects, which can influence signal interpretation depending on dye ratios a
Pureté et documentation
-
Fiche technique (276 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)